Tokyo, Japan

Yuichiro Taira

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019-2021

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Yuichiro Taira: Innovator in Cancer Therapy

Introduction

Yuichiro Taira is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer therapy through his innovative research and patents. With a total of 2 patents, Taira is dedicated to advancing medical science and improving treatment options for cancer patients.

Latest Patents

Taira's latest patents focus on recombinant obligate anaerobic Gram-positive bacteria. The primary objective of these inventions is to effectively induce cancer cell apoptosis using anti-TRAIL-R1 and anti-TRAIL-R2 antibodies. This innovative approach aims to reduce the toxicity imposed on normal cells while targeting cancer cells. The patents detail the use of recombinant bacteria that include nucleic acids encoding fusion proteins with multiple anti-TRAIL-R1 and anti-TRAIL-R2 single-chain antibodies, ensuring they are in an expressible state.

Career Highlights

Yuichiro Taira is affiliated with Teikyo Heisei University, where he conducts his research and development. His work is characterized by a commitment to finding effective solutions for cancer treatment, showcasing his expertise in biotechnology and molecular biology.

Collaborations

Taira collaborates with notable colleagues, including Takeshi Nishikawa and Ikuko Taira. These partnerships enhance the research efforts and contribute to the innovative environment at Teikyo Heisei University.

Conclusion

Yuichiro Taira's contributions to cancer therapy through his patents and research exemplify his dedication to improving medical treatments. His innovative work continues to inspire advancements in the field of biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…